Susquehanna Fundamental Investments LLC Invests $1.09 Million in Embecta Corp. (NASDAQ:EMBC)

Susquehanna Fundamental Investments LLC acquired a new stake in Embecta Corp. (NASDAQ:EMBC) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 52,743 shares of the company’s stock, valued at approximately $1,089,000. Susquehanna Fundamental Investments LLC owned about 0.09% of Embecta as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Embecta by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 7,025,483 shares of the company’s stock worth $145,076,000 after purchasing an additional 28,031 shares during the period. American Century Companies Inc. increased its holdings in shares of Embecta by 8.0% in the 4th quarter. American Century Companies Inc. now owns 3,261,934 shares of the company’s stock valued at $67,359,000 after acquiring an additional 242,668 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in Embecta during the fourth quarter worth approximately $15,270,000. Bank of New York Mellon Corp lifted its position in Embecta by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company’s stock valued at $14,155,000 after acquiring an additional 4,769 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Embecta by 14.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 566,993 shares of the company’s stock valued at $11,708,000 after purchasing an additional 73,165 shares during the last quarter. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta Stock Up 0.7 %

NASDAQ EMBC opened at $12.28 on Friday. The firm has a 50-day moving average price of $12.54 and a 200 day moving average price of $15.79. Embecta Corp. has a 52-week low of $10.10 and a 52-week high of $21.48. The stock has a market capitalization of $713.89 million, a P/E ratio of 12.28, a P/E/G ratio of 0.78 and a beta of 1.23.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. On average, equities research analysts expect that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 4.89%. The ex-dividend date was Friday, February 28th. Embecta’s dividend payout ratio (DPR) is presently 60.00%.

Analyst Upgrades and Downgrades

Separately, Mizuho began coverage on shares of Embecta in a research note on Thursday, April 10th. They set a “neutral” rating and a $15.00 price target for the company.

Insider Buying and Selling at Embecta

In related news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total transaction of $50,778.00. Following the sale, the director now owns 36,133 shares of the company’s stock, valued at $591,858.54. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.42% of the company’s stock.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.